{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:12:27Z","timestamp":1780078347234,"version":"3.54.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000074","name":"U.S. Department of Justice","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.japh.2020.07.015","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T07:36:26Z","timestamp":1597390586000},"page":"e205-e214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-7455","authenticated-orcid":false,"given":"Kelsi L.","family":"Hines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen K.","family":"Garofoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Garofoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy M.","family":"Elswick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Winstanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.japh.2020.07.015_bib2","first-page":"631","article-title":"Opioid overdose prevention programs providing naloxone to laypersons \u2013 United States, 2014","volume":"64","author":"Wheeler","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"10.1016\/j.japh.2020.07.015_bib3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","article-title":"Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine","volume":"79","author":"Strang","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.japh.2020.07.015_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2020.07.015_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.04.020","article-title":"State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies","volume":"189","author":"Xu","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2020.07.015_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","article-title":"Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid","volume":"190","author":"Gertner","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"31","key":"10.1016\/j.japh.2020.07.015_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018","volume":"68","author":"Guy","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.japh.2020.07.015_bib9","first-page":"270","article-title":"Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States","volume":"188","author":"Lamdin","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"2S","key":"10.1016\/j.japh.2020.07.015_bib10","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2020.07.015_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.japh.2019.11.024","article-title":"Naloxone availability and dispensing in Indiana pharmacies 2 years after implementation of a statewide standing order","volume":"60","author":"Eldridge","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2020.07.015_bib12","first-page":"153","article-title":"A\u00a0systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.japh.2020.07.015_bib13","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.japh.2020.07.015_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jac5.1171","article-title":"Pharmacists and the opioid crisis: a narrative review of pharmacists\u2019 practice roles","volume":"3","author":"Bratberg","year":"2019","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"4","key":"10.1016\/j.japh.2020.07.015_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2105\/AJPH.2016.303062","article-title":"Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013","volume":"106","author":"Jones","year":"2016","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.japh.2020.07.015_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08897077.2018.1455163","article-title":"An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines","volume":"39","author":"Zaman","year":"2018","journal-title":"Subst Abus"},{"key":"10.1016\/j.japh.2020.07.015_bib17","unstructured":"Winstanley EL, Clark A, Jamison S. Evaluation of an Opioid Overdose Prevention Program: final report for the Center for Chemical Addiction Treatment (CCAT). Cincinnati, Ohio. January, 2015."},{"key":"10.1016\/j.japh.2020.07.015_bib18","series-title":"Stata Statistical Software: Release 15. TX: College Station","year":"2017"},{"issue":"1","key":"10.1016\/j.japh.2020.07.015_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19066","article-title":"Association of Medicaid expansion with opioid overdose mortality in the United States","volume":"3","author":"Kravitz-Wirtz","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.japh.2020.07.015_bib20","first-page":"300","article-title":"Prescribe to Prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists","volume":"10","author":"Lim","year":"2016","journal-title":"J\u00a0Addict Med"},{"issue":"4","key":"10.1016\/j.japh.2020.07.015_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/add.13255","article-title":"Tangled-up and blue: releasing the regulatory chokehold on take-home naloxone","volume":"111","author":"Winstanley","year":"2016","journal-title":"Addiction"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912030340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912030340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:49:26Z","timestamp":1761544166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912030340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S154431912030340X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.015","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}